VIASYS Healthcare's Critical Care Division Announces FDA Clearance of AVEA.Business Editors and Health/Medical Writers CONSHOHOCKEN, Pa.--(BW HealthWire)--May 23, 2002 VIASYS Healthcare Inc.'s (NYSE NYSE See: New York Stock Exchange :VAS) Critical Care Division today announced that it received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clearance of a 510(k) pre-market notification to market the AVEA AVEA American Veterinary Exhibitors Association (TM) ventilator. AVEA is an advanced generation integrated life support system designed to meet the needs of all neonatal, pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. and adult patients. VIASYS anticipates that it will begin shipment of the product to customers before the end of the third quarter of 2002. VIASYS Healthcare is a global, research-based medical technology company focused in respiratory technology, neuro-care and medical/surgical products. VIASYS' products are marketed under well-recognized brand names such as SensorMedics, Bird, Bear, Nicolet, and Jaeger jaeger (yā`gər), common name for several members of the family Stercorariidae, member of a family of hawklike sea birds closely related to the gull and the tern. The skua is also a member of this family. . VIASYS has headquarters in Conshohocken. More information can be found at www.viasyshealthcare.com. This news release includes a forward-looking statement within the meaning of the "Safe Harbor" provisions of Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 regarding commencement of shipments of AVEA. This forward-looking statement is based on current expectations and involves inherent risks and uncertainties, including important factors that could delay, divert, or change the expectations for AVEA and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, marketing initiatives, governmental regulations and legislation, patent positions and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . For further details and a discussion other risks and uncertainties that may change VIASYS' expectations, please see the company's Annual Report on Form 10-K for the year ended Dec. 29, 2001, which is on file with the Securities and Exchange Commission. VIASYS undertakes no obligation to publicly update this forward-looking statement, whether as a result of new information, future events, or otherwise. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion